CFMATTERS

CFMATTERS Advisory Boards

CFMATTERS is supported by two advisory boards – the Scientific Advisory Board and the Ethics, Data and Safety Review Group. These boards shall not only ensure the highest standard of research and monitor the progress of the project by taking part in the annual meetings, but will also ensure the compliance with all necessary ethical regulations. Whenever appropriate, they will consult the consortium and make recommendations on how to best improve project performance.

Scientific Advisory Board (SAB)

The Scientific Advisory Board will consist of independent members with established international acknowledged expertise in field of Acute & Chronic Bacterial Infection, Cystic Fibrosis, Microbiome analysis, Innate immunity, disease models and the conduct of clinical trials and research ethics. The SAB will provide final study approval to any required trial amendments representing the key aspects of activities of the project, as indicated by the Work packages. The potential members have been nominated before the initiation of the project and have agreed to take on the responsibility.

 

The Scientific Advisory Board will ensure a high standard of research and monitor the progress of the project by taking part in the annual General Assembly meetings. Whenever appropriate, it will consult the consortium and make recommendations as to improve their performance.

 

Ethics, Data and Safety Review Group (EDSRG)

The EDSRG will consist of 3 independent experts with combined expertise in research ethics, cystic fibrosis, and clinical trials and will include a patient representative. The Group members will review data forwarded by the Trial Coordination Centre (undefinedWP01) twice yearly. The members are:

  • Dr. Edward McKone a CF Clinician and established European Clinical Trial expert,
  • Ms. Ulrike Pypops a European Lawyer with Cystic Fibrosis who has extensive clinical trial ethical experience and
  • Professor Scott Bell an International CF Clinician from outside the jurisdiction of the trial (Australia) with significant experience with both clinical trials and translational research.

 

 

 

 

 

 

 

 

 

 

Home
Menu
Search
Top

Newsletter Subscription

News Section

More than 200 patients recruited to the CFMATTERS study Read more

Social Media

Facebook CFMATTERS LinkedIn CFMATTERS
Home
Menu
Search
Top